Positive nodes were found to be associated with significantly shorter survival (HR 2.29; 1.17–4.47; p = 0.015), whilst patients with HER2-positive tumours were at reduced risk of death (HR 0.500; 0.311–0.802; p = 0.004). Here, ERBB2 is linked to neoplasm.